MPH MITTELSTAENDISCHE PHARMA HOLDING AG 
By May 30, 2014
MPH Mittelständische Pharma Holding AG: IFRS-results Q1 2014: Sales of EUR 56.17 million, net profit of EUR 2.95 million, profit growth of + 46.7 %MPH Mittelständische Pharma Holding AG, Berlin (ISIN: DE000A0NF697), today reports its IFRS Group results for the first quarter of 2014.
In the first three months 2014 the MPH Group achieved sales amounting to EUR 56.17 million (prior-year period: EUR 53.42 million), with thus representing an increase of + 5.1 % compared to the same period of the previous year. Net profit was EUR 2.95 million (prior-year period: EUR 2.01 million), reaching a margin of 5.2 %. Compared to the previous year profit growth reached + 46.7 %.
About MPH Mittelständische Pharma Holding AG:
The company MPH Mittelständische Pharma Holding AG, based in Berlin, has strategically concentrated its activities on the growth segments of the
healthcare market and is aimed to make a contribution towards cutting costs
in the healthcare system.
The focus lies on medicines manufactured on the basis of patent-free and patent-protected active substances for the therapy of chronic diseases. Complementary, services for individual patient therapies, aesthetic surgeries and other medical treatments are offered along the value-added-chain in the healthcare market.
MPH Mittelständische Pharma Holding AG is listed in the Entry Standard (Open
Market) of the Frankfurt stock exchange.
Key figures for the share of MPH Mittelständische Pharma Holding AG: Subscribed capital: EUR 41.167.155
Listed shares: Preference shares
Number of preference shares in circulation: 19.025.000
ISIN: DE000A0NF697
WKN: A0NF69
Stock symbol: 93MV
MPH Mittelständische Pharma Holding AG Linda Reichelt
Fasanenstraße 77 Phone +49 (0) 30 897 30 86
60
E-Mail: ir@mph-ag.de
D-10623 Berlin Fax: +49 (0) 30 897 30 86 69 Web: www.mph-ag.de
|
distributed by
|
